TY - JOUR
T1 - Neurotheranostics as personalized medicines
AU - Kevadiya, Bhavesh D.
AU - Ottemann, Brendan M.
AU - Thomas, Midhun Ben
AU - Mukadam, Insiya
AU - Nigam, Saumya
AU - McMillan, Jo Ellyn
AU - Gorantla, Santhi
AU - Bronich, Tatiana K.
AU - Edagwa, Benson
AU - Gendelman, Howard E.
PY - 2019/8
Y1 - 2019/8
N2 - The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide “optimal” therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.
AB - The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide “optimal” therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.
KW - Alzheimer's disease (AD)
KW - Blood brain barrier (BBB)
KW - Brain-targeted nanoparticles
KW - Magnetic resonance imaging (MRI)
KW - Nanomedicine
KW - Neurodegenerative disorders
KW - Neuroimaging
KW - Neurotheranostics
KW - Parkinson's disease (PD)
KW - Single photon emission computed tomography (SPECT/CT)
KW - Theranostics
UR - http://www.scopus.com/inward/record.url?scp=85056173576&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056173576&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2018.10.011
DO - 10.1016/j.addr.2018.10.011
M3 - Review article
C2 - 30421721
AN - SCOPUS:85056173576
VL - 148
SP - 252
EP - 289
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
SN - 0169-409X
ER -